Zoetis Inc. $ZTS Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 502,963 shares of the company’s stock after selling 27,242 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.11% of Zoetis worth $73,594,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZTS. Savvy Advisors Inc. boosted its position in Zoetis by 54.0% during the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares during the last quarter. Sound Income Strategies LLC lifted its stake in shares of Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock worth $67,000 after purchasing an additional 152 shares during the period. Chicago Partners Investment Group LLC boosted its holdings in shares of Zoetis by 67.0% during the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after purchasing an additional 1,961 shares during the last quarter. QRG Capital Management Inc. grew its position in shares of Zoetis by 4.9% in the second quarter. QRG Capital Management Inc. now owns 77,741 shares of the company’s stock valued at $12,124,000 after purchasing an additional 3,616 shares during the period. Finally, Consolidated Investment Group LLC increased its stake in Zoetis by 59.6% in the second quarter. Consolidated Investment Group LLC now owns 26,235 shares of the company’s stock valued at $4,091,000 after purchasing an additional 9,800 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 1.1%

Shares of NYSE ZTS opened at $123.24 on Wednesday. The stock has a fifty day moving average price of $123.37 and a 200 day moving average price of $138.85. The company has a market cap of $54.31 billion, a P/E ratio of 20.75, a P/E/G ratio of 2.53 and a beta of 0.97. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZTS. KeyCorp initiated coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Wednesday, December 3rd. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Finally, Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.